- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01382901
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
January 22, 2018 updated by: American Regent, Inc.
A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects > or = to 18 years old, and able to give informed consent to the study.
- RLS signs and symptoms affirming diagnosis. The IRLS Diagnostic Criteria for RLS must be met.
- Subjects have RLS symptoms > or = to 5 nights per week for at least the past 3 months.
- A baseline score > or = to 15 on the IRLS Rating Scale.
- At least one leg with an average baseline Periodic Leg Movement while asleep (PLMS) > or = to 15 movements per hour and at least 3 days of baseline PLMS data is measurable in each leg.
- Subjects on anti-depressants, sleep medications, dopamine agonists, benzodiazepines, narcotics or other RLS treatments must be off therapy at least one week or 5 half lives, whichever is longer before any baseline RLS assessments and PLM measurements are obtained.
- Subject has regular sleep hours between 9 p.m. and 9 a.m.
- Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control.
Exclusion Criteria:
- RLS 2° to other CNS disease or injury. Such disorders include peripheral neuropathy, neurodegenerative disorders, and multiple sclerosis.
- RLS 2° to Chronic Kidney Disease.
- Any pain related or sleep related disorders (e.g. sleep apnea) which may confound the outcome measures.
- History of neuroleptic akathisia.
- Oral iron use (including multivitamins with iron) after screening.
- Parenteral iron use within 4 weeks prior to screening.
- Parenteral iron use > 125 mg per week within 4 to 8 weeks prior to screening.
- History of > or = to 10 blood transfusions in the past 2 years.
- Anticipated need for blood transfusion during the study.
- Known hypersensitivity reaction to any component to FCM.
- Previously participated in an FCM clinical trial.
- Chronic or serious active severe infection.
- Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for > 5 years).
- Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
- Receiving prescription medication for the treatment of bronchospasm.
- Pregnant or lactating women.
- Severe peripheral vascular disease with significant skin changes.
- Seizure disorder currently being treated with medication.
- Baseline ferritin > 300 ng/mL.
- Baseline TSAT > or = to 45%.
- History of hemochromatosis or hemosiderosis or other iron storage disorders.
- AST or ALT greater than the upper limit of normal.
- Hemoglobin greater than the upper limit of normal.
- Calcium or phosphorous outside the normal range.
- Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.
- Known positive HIV-1/HIV-2 antibodies (anti-HIV).
- Received an investigational drug within 30 days before randomization.
- Chronic alcohol or drug abuse within the past 6 months.
- Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) III or IV, or poorly controlled hypertension according to the judgment of the investigator.
- Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
- Subject unable to comply with study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Intravenous (IV) Iron
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Restless Legs Syndrome (IRLS) Total Score
Time Frame: Change from Baseline to Day 28
|
The scale represents the patients symptoms of RLS.
The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.
|
Change from Baseline to Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
July 1, 2007
Study Completion (Actual)
July 1, 2007
Study Registration Dates
First Submitted
February 23, 2011
First Submitted That Met QC Criteria
May 31, 2011
First Posted (Estimate)
June 27, 2011
Study Record Updates
Last Update Posted (Actual)
February 20, 2018
Last Update Submitted That Met QC Criteria
January 22, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1VIT05009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome (RLS)
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
XenoPort, Inc.CompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Seton Healthcare FamilyCompleted
-
GlaxoSmithKlineCompleted12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome ((CR-RLS))Restless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
University Hospital, MontpellierCompletedRestless Legs Syndrome (RLS)France
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States